Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook art

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurre

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's f

Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 bill

Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval fo

Arrowstreet Capital Limited Partnership acquired a new stake in shares of Precigen, Inc. (NASDAQ: PG

Wall Street analysts changed outlook on top names. UBS cut Fidelity National Information target, JP

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

Precigen NASDAQ: PGEN reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch,

Precigen, Inc. (PGEN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consens

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior q

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a B

GERMANTOWN, Md., July 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage bio

CFO Harry Thomasian Jr. sold 200,000 shares of Precigen common stock across two transactions for a t

Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue g

Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs

41,884 shares were sold in an open-market transaction for a total of ~$183,000 on May 28, 2026. The

Third annual RRP Awareness Day highlights the experiences of people living with recurrent respirator

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's f

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respirat

Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and ra

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

Cisco Inc (NASDAQ: CSCO) beat expectations and raised guidance with $15.84B revenue and $1.06 EPS. S

Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.02) per share which met the analyst consensu

Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medic

The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, w

Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating esti

Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainer

Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and ra

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

Shares of Navan Inc (NASDAQ: NAVN) spiked in pre-market trading on better-than-expected Q4 results.

Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.01) per share which beat the analyst consens

 Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the adv